NASDAQ:LIFE aTyr Pharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding aTyr Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.85 -0.01 (-0.26 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$3.80Now: $3.85▼$3.9450-Day Range$3.59MA: $3.99▼$4.5752-Week Range$2.13Now: $3.85▼$7.62Volume15,837 shsAverage Volume211,711 shsMarket Capitalization$36.72 millionP/E RatioN/ADividend YieldN/ABeta2.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a collaboration with the University of Nebraska Medical Center for the development of neuropilin-2 receptor biology; and a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. The company was founded in 2005 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingaTyr Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, aTyr Pharma has a forecasted upside of 211.7% from its current price of $3.85.Amount of Analyst CoverageaTyr Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesaTyr Pharma has received 386 “outperform” votes. (Add your “outperform” vote.)Underperform VotesaTyr Pharma has received 446 “underperform” votes. (Add your “underperform” vote.)Community SentimentaTyr Pharma has received 53.61% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote “Outperform” if you believe LIFE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,973.00 in company stock.Percentage Held by InsidersOnly 9.44% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions58.79% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for aTyr Pharma are expected to decrease in the coming year, from ($2.11) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:LIFE Previous Symbol CUSIP53217V10 CIK1339970 Webwww.atyrpharma.com Phone858-731-8389Debt Debt-to-Equity RatioN/A Current Ratio4.47 Quick Ratio4.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$420,000.00 Price / Sales87.42 Cash FlowN/A Price / Cash FlowN/A Book Value$5.40 per share Price / Book0.71Profitability EPS (Most Recent Fiscal Year)($7.03) Net Income$-23,600,000.00 Net Margins-190.06% Return on Equity-51.92% Return on Assets-35.86%Miscellaneous Employees42 Outstanding Shares9,537,000Market Cap$36.72 million Next Earnings Date11/12/2020 (Estimated) OptionableOptionable $3.85 -0.01 (-0.26 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive LIFE News and Ratings via Email Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions How has aTyr Pharma's stock been impacted by Coronavirus (COVID-19)? aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LIFE shares have increased by 27.1% and is now trading at $3.85. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of aTyr Pharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for aTyr Pharma. When is aTyr Pharma's next earnings date? aTyr Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for aTyr Pharma. How were aTyr Pharma's earnings last quarter? aTyr Pharma Inc (NASDAQ:LIFE) posted its earnings results on Thursday, August, 13th. The biotechnology company reported ($0.69) EPS for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.04. aTyr Pharma had a negative return on equity of 51.92% and a negative net margin of 190.06%. View aTyr Pharma's earnings history. When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work? aTyr Pharma shares reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split. What price target have analysts set for LIFE? 3 brokerages have issued 12-month price objectives for aTyr Pharma's shares. Their forecasts range from $8.00 to $15.00. On average, they anticipate aTyr Pharma's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 211.7% from the stock's current price. View analysts' price targets for aTyr Pharma. Who are some of aTyr Pharma's key competitors? Some companies that are related to aTyr Pharma include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Waters (WAT), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and BG Medicine (BGMD). View all competitors. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), SCYNEXIS (SCYX), Biocept (BIOC), Idera Pharmaceuticals (IDRA), Fulcrum Therapeutics (FULC), NVIDIA (NVDA), Precigen (PGEN), QUALCOMM (QCOM), Viking Therapeutics (VKTX) and VIVUS (VVUS). Who are aTyr Pharma's key executives? aTyr Pharma's management team includes the following people: Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)Ms. Jill M. Broadfoot, CFO & Principal Accounting Officer (Age 57)Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)Dr. David J. King, Scientific Consultant (Age 60)Xiang-Lei Yang Ph.D., Founder When did aTyr Pharma IPO? (LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. What is aTyr Pharma's stock symbol? aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE." Who are aTyr Pharma's major shareholders? aTyr Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alyeska Investment Group L.P. (7.76%) and Two Sigma Advisers LP (0.85%). Company insiders that own aTyr Pharma stock include Jill Marie Broadfoot, John K Clarke, John Mendlein, Nancy Krueger, Paul Schimmel and Sanjay Shukla. View institutional ownership trends for aTyr Pharma. Which institutional investors are selling aTyr Pharma stock? LIFE stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P.. View insider buying and selling activity for aTyr Pharma. Which institutional investors are buying aTyr Pharma stock? LIFE stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, John Mendlein, Paul Schimmel, and Sanjay Shukla. View insider buying and selling activity for aTyr Pharma. How do I buy shares of aTyr Pharma? Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is aTyr Pharma's stock price today? One share of LIFE stock can currently be purchased for approximately $3.85. How big of a company is aTyr Pharma? aTyr Pharma has a market capitalization of $36.72 million and generates $420,000.00 in revenue each year. The biotechnology company earns $-23,600,000.00 in net income (profit) each year or ($7.03) on an earnings per share basis. aTyr Pharma employs 42 workers across the globe. What is aTyr Pharma's official website? The official website for aTyr Pharma is www.atyrpharma.com. How can I contact aTyr Pharma? aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
